About Bioaffinity technologies
Bioaffinity technologies is a publicly listed company based in San Antonio (United States) founded in 2014. IVD platforms are developed to detect and target cancer cells. Bioaffinity technologies has raised $9.05 million across 6 funding rounds from investors including sanantonioedf. The company has 57 employees. Bioaffinity technologies offers products and services including CyPath Lung and OncoSelect Therapeutics. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its legal entity is BIOAFFINITY TECHNOLOGIES, INC. Its competitors include Cytek Biosciences, ACEA Biosciences and Accuri Cytometers; 3 of its 3 listed competitors have raised funding.
Company details
Bioaffinity Technologies was founded in 2014 in San Antonio, United States, within the biotechnology sector. Operations focus on designing diagnostic and therapeutic platforms for various cancers. In vitro diagnostics (IVD) are developed alongside targeting methods for cancer cells. The initial product, CyPath, utilizes a biolabel that induces fluorescence in cancer cells to enable detection. Activities emphasize early identification and treatment options in oncology.
- Headquarters San Antonio, United States
- Employees 57
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bioaffinitytech.com
- Social LinkedIn X Facebook
- Legal Name Bioaffinity Technologies, Inc.
- Annual Revenue$6.16 M (USD)-34.18as on Dec 31, 2025
- Net Profit-$14.91 M (USD)-64.93as on Dec 31, 2025
- EBITDA-$10.07 M (USD)-20.6as on Dec 31, 2025
- Total Equity Funding$9.05M (USD)
in 6 rounds
- Latest Funding Round$1.2M (USD), Post-IPO
Aug 2025
- Investors
- Employee Count57
Products & Services of Bioaffinity technologies
Bioaffinity technologies offers a comprehensive portfolio of products and services, including CyPath Lung and OncoSelect Therapeutics.
Non-invasive test using flow cytometry for early lung cancer detection.
Research on cancer-selective therapies targeting tumor cells.
Funding Insights of Bioaffinity technologies
Bioaffinity technologies has successfully raised a total of $9.05M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.2 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.05M
- Total Rounds 6
- Last Round Post-IPO — $1.2M
- First Round $150,000
(Mar 2017)
- Investors Count 1
All 6 funding rounds of Bioaffinity technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $1.2M | Post-IPO | – | – | – |
| Aug 2024 | $1.3M | Post-IPO | – | – | – |
| Mar 2024 | $2.62M | Post-IPO | – | – | – |
| Jul 2020 | $5M | Series B | – | – | – |
| Jul 2017 | $4.05M | Series A | – | – | – |
| Mar 2017 | $150,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Bioaffinity technologies
Bioaffinity technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include sanantonioedf.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides recruitment services to connect organizations with qualified candidates. | 2000 | sanantonioedf.com | San Antonio, United States |
Investor details for Bioaffinity technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bioaffinity technologies
15 people are tracked at Bioaffinity technologies (6 in leadership, 6 in board & advisors, 3 in team); the tracked headcount is 57.
| Name | Role | Group |
|---|---|---|
Jennifer Rebeles | Director, Diagnostics | Leadership |
Xavier T. Reveles | VP, Operations | Leadership |
Maria Zannes | CEO, President & Director | Leadership |
David Elzi | VP, Research | Leadership |
Michael Dougherty | VP & CFO | Leadership |
Vivienne I. Rebel | EVP, Chief Science & Medical Officer | Leadership |
Steven Girgenti | Chairman, Board of Directors | Board & advisors |
Gary Rubin | Director | Board & advisors |
Stuart Diamond | Director | Board & advisors |
Robert A. Anderson | Director | Board & advisors |
Peter S. Knight | Director | Board & advisors |
Mohsin Y. Meghji | Director | Board & advisors |
Timothy P. Zannes | EVP, General Counsel & Secretary | Team |
Shao-Chiang Lai | Staff Scientist, Diagnostics | Team |
William Bauta | SVP, Therapeutics | Team |
Complete people profiles for Bioaffinity technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bioaffinity technologies
Bioaffinity technologies is a publicly listed company on the NASDAQ with ticker symbol BIAF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Sep 2022
- Listed onNASDAQ: BIAF
- Listed entitybioAffinity Technologies, Inc.
- Exchange sectorHealth technology
- ISINUS09076W4069
- Share price$3.62 (-7.05% on the day) · 2026-10-13
- Market capitalisation$4.7M
- EPS (diluted, trailing year)$-103.29
- Volume (last session)892,274
Financials of Bioaffinity technologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $6.2M | -$14.9M | -$10.1M |
| 2024 | $9.4M | -$9.0M | -$8.3M |
| 2023 | $2.5M | -$7.9M | -$7.7M |
| 2022 | $4,800 | -$8.2M | -$4.0M |
| 2021 | -$6.3M | -$2.2M |
Detailed financial statements for Bioaffinity technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Bioaffinity technologies
4 dated milestones of Bioaffinity technologies across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Bioaffinity technologies is founded.
- Funding First funding round of $150K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $1.2M.
Competitors of Bioaffinity technologies
Bioaffinity technologies has 3 listed competitors in our database, 3 of them funded. They include Cytek Biosciences, ACEA Biosciences and Accuri Cytometers.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cytekbio.com | 2014 | San Francisco, United States | $132M | 676 | Advanced flow cytometry systems are manufactured for research applications. | |
| aceabio.com | 2002 | San Diego, United States | $37.89M | 5,968 | Instruments for life science research are developed and marketed. | |
| accuricytometers.com | 2004 | Ann Arbor, United States | $30.91M | Compact flow cytometers for cell analysis are developed and provided. |
Detailed competitors of Bioaffinity technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bioaffinity technologies
The website of Bioaffinity technologies (bioaffinitytech.com) receives about 3.2K visits a month.
- Monthly visits3.2K
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Bioaffinity technologies (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioaffinity Technologies
Complete news archive for Bioaffinity technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioaffinity technologies
Bioaffinity technologies was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Bioaffinity technologies is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
Bioaffinity technologies is a funded company, having raised a total of $9.05M across 6 funding rounds to date. The company's 1st funding round was a Grant of $150K, raised on Mar 2017.
Bioaffinity technologies has 57 employees.
Annual revenue of Bioaffinity technologies is $6.16M as on Dec 31, 2025.
Bioaffinity Technologies was founded in 2014 in San Antonio, United States, within the biotechnology sector. Operations focus on designing diagnostic and therapeutic platforms for various cancers. In vitro diagnostics (IVD) are developed alongside targeting methods for cancer cells. The initial product, CyPath, utilizes a biolabel that induces fluorescence in cancer cells to enable detection. Activities emphasize early identification and treatment options in oncology.
Bioaffinity technologies's top competitors include Cytek Biosciences, Accuri Cytometers and ACEA Biosciences.
Bioaffinity technologies offers CyPath Lung and OncoSelect Therapeutics.
Yes, Bioaffinity technologies is publicly traded on NASDAQ under the ticker symbol BIAF.
Bioaffinity technologies has 1 investor. Key investors include sanantonioedf.
Bioaffinity technologies operates through Bioaffinity Technologies, Inc..